Novel therapeutics for alcoholic hepatitis - Cleveland Translational Component
Description: Alcohol abuse is a leading cause of morbidity and mortality worldwide. In the US, 18 million Americans abuse alcohol, with alcoholic liver disease affecting over 10 million people. Alcohol abuse's deleterious effects on the liver leads to pathologically distinct entities: steatosis, steatohepatitis (ASH), fibrosis and cirrhosis. Disease progression ony occurs in a sub-set of heavy drinkers, suggesting a role for genetic and environmental risk factors. There is a pressing clinical need to develop improved therapies for patients with ASH, as the current strategy of glucocorticoid (GC) treatment is only effective in a sub-set of patients The goals of this application are to advance the development of novel therapeutic strategies for the treatment of ASH by 1) identification and validation of new drug targets and therapeutic strategies by making use of pre-clinical mouse models of ASH, 2) development of rationally designed and innovative biomarkers that will improve our ability to diagnose ASH and rapidly determine the efficacy of treatment strategies and 3) understanding the genetic contributions to both the severity of ASH and sensitivity to therapeutic intervention.
Funding type: cooperative_agreement
Funder scheme: U01
Start date: 2012-09-20
End date: 2018-06-30
Investigator: LAURA E. NAGY (lead)
Institutions: Cleveland Clinic Lerner College of Medicine, CLEVELAND CLINIC LERNER COM-CWRU
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Funded outputs count: 108
Funder award ID: U01AA021890
OpenAlex ID: G1214492011